Drug approval is not the end of learning — it should be the beginning. StoryMD gives pharmaceutical companies continuous, AI-powered real-world evidence from the patients living with their therapies every day.
After years of investment and a successful trial, approved drugs enter an invisible world. The patients, behaviors, and variables that determine real therapeutic value simply vanish from view.
Not claims data. Not EHR extraction. Not a survey. StoryMD collects structured, prospective, consent-based data from real patients in real time — across every dimension of human experience that determines drug performance.
Every patient enters data through the same AI-guided interface — creating a dataset with no definitional drift, no methodology gaps, no variation in variable definition. This is what makes it AI-analyzable at population scale.
Unlike claims data or EHR aggregation, StoryMD data is collected in real time as patients live their disease. No reconstruction. No inference. The data reflects what actually happened, when it happened.
A clinical trial closes. A StoryMD dataset never does. Every new month deepens the asset. Years of patient journeys compound into insights that simply cannot exist in time-limited studies.
It captures the full human context: what patients eat, how they sleep, what stresses them, where they live — the factors that govern real drug performance but never appear in a trial case report form.
The dataset is the foundation. AI is the engine that transforms it into competitive advantage — surfacing patterns across your therapy's real-world performance that have never existed in any prior study.
In a controlled trial, you never see a competitor. In the real world, patients switch, combine, and compare therapies every day. StoryMD makes that visible — and actionable.
Compare adherence, symptom resolution, quality-of-life improvements, and discontinuation between your drug and therapeutic alternatives — without designing a comparative trial.
Understand exactly which patients switch away from your therapy, when, and what they switch to. Then understand why — and intervene with evidence-based strategies.
Identify how your drug's tolerability compares across subpopulations. Discover areas of genuine advantage and areas requiring clinical attention — before they surface elsewhere.
Understand how your drug performs as first-line, second-line, and in combination with other therapies — a complete view of your drug's position across the real therapeutic landscape.
Each stream feeds the AI engine that powers the intelligence above. Together they create a patient portrait no trial, claims database, or EHR system has ever assembled.
Labs, imaging, provider visits, diagnoses — the objective record of disease and treatment response.
Exact dosing patterns, missed doses, switches — the real story of how patients take their therapy.
Patient-reported symptoms tracked over months and years — the longitudinal arc no trial captures.
Continuous heart rate, sleep quality, activity levels, HRV, and glucose data from integrated devices.
Diet, exercise, stress, environmental factors — the daily variables that drive real-world performance.
Concurrent medications, dosing adjustments, prior therapies — the full therapeutic context.
Age, ethnicity, comorbidities, and genetic factors that influence response across populations.
Direct patient voice — quality of life, functional status, and the experience of living with the disease.
Pattern detection across all streams — surfacing what no individual data point can reveal alone.
StoryMD data doesn't sit in one department. It flows across the entire pharma organization — giving each function exactly the intelligence they need to do their best work.
The intelligence extends beyond your walls. Patients and caregivers gain a unified view of their health journey and personalized disease insights. Disease foundations earn co-authorship on top-tier publications and sustainable funding through the partnership. Every party advances — because the data serves everyone, in proportion to the trust they helped build.
StoryMD transforms what happens after a drug is approved. The dataset never closes — and every new patient enrolled makes the intelligence deeper, more precise, and more valuable.
Participation in StoryMD positions your company as the pharmaceutical leader that didn't stop learning after approval — that treated patients as partners in discovery, not endpoints in a study.
RWE-generation partnerships signal scientific rigor and long-term commitment. Foundation-governed data strengthens label expansion applications and post-market credibility.
KOLs and providers trust companies that provide real-world outcome data, not just trial summaries. Medical Affairs gets evidence that changes how physicians prescribe.
Patients and disease foundations choose the company that continued to care — and continued to learn — after the trial ended. Sponsoring StoryMD signals scientific commitment, not marketing.
AI-driven drug lifecycle intelligence signals technological leadership and long-term pipeline de-risking. The company that builds the deepest post-approval intelligence layer sets the standard.
Every day without post-approval intelligence is a day your drug's real-world story goes unwritten. The platform is ready. The foundation partners are engaged. The window to define this category is open now.
Meet the StoryMD team and explore fit for your drug indication and therapeutic area.
Engage your Medical Affairs and R&D leads to identify the indication where real-world evidence matters most.
We co-design the program, onboard the foundation partner, and deliver your first real-world insights within 90 days.